You are here

  • Home
  • Archive
  • Volume 33, Issue Suppl 4
  • PR072/#1519  Effort: clinical and molecular features associated with clinical benefit from adavosertib with or without olaparib in recurrent ovarian cancer following progression on PARP inhibition (NCT03579316)

Article info

Article menu

Download PDFPDF

Featured Posters: Poster Rounds with the Professors
AS11. Ovarian cancer
PR072/#1519  Effort: clinical and molecular features associated with clinical benefit from adavosertib with or without olaparib in recurrent ovarian cancer following progression on PARP inhibition (NCT03579316)
Free

Authors

Citation

Adjei N, Coleman R, Fellman B, et al
PR072/#1519  Effort: clinical and molecular features associated with clinical benefit from adavosertib with or without olaparib in recurrent ovarian cancer following progression on PARP inhibition (NCT03579316)
International Journal of Gynecologic Cancer 2023;33:A71-A73.

Publication history

  • First published November 7, 2023.
Online issue publication 
November 07, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.